Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34

Innoviva, Inc.

Innoviva, Inc.

INVA

0.00

Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ: INVA) with a Overweight and lowers the price target from $36 to $34.